Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chugai Applies for Capecitabine + Bevacizumab + Oxaliplatin Regimen
March 10, 2008
- MEDICAL DEVICE NEWS IN BRIEF
March 10, 2008
- Takeda Applies for Ramelteon for the Treatment of Insomnia
March 10, 2008
- Reward Good DPC Hospitals by Introducing Japanese Version of P4P: Prof. Muto
March 10, 2008
- Acute-Stage Indications for Piroxicam Deleted: Korosho
March 10, 2008
- Number of DPC Hospitals to Increase to 718 in FY2008
March 10, 2008
- PMDA Announces Draft Operation and System Optimization Plan
March 10, 2008
- Range of Public Healthcare Benefits to Become Center of Discussions
March 10, 2008
- REGULATORY NEWS IN BRIEF
March 10, 2008
- Takashi Kodama Elected JPA President
March 10, 2008
- Kitasato Univ.-Harvard School of Public Health Symposium
March 10, 2008
- Ethical Drugs Market Exceeds \8 Trillion in 2007: IMS
March 10, 2008
- Kyowa Hakko Licenses Antibody for Cancer Treatment
March 10, 2008
- Nucleic Acid-Based Drugs Will Be Innovative Drugs of Next Generation: Prof. Morishita
March 10, 2008
- Pfizer Japan Mobilizes All Employees, Officers to Defend Market for Norvasc
March 10, 2008
- GCP for Medical Devices to Be Amended
March 10, 2008
- TOPICS／Dr Karasawa Will Soon Be Back to Office: JMA
March 10, 2008
- Teijin's Gout Treatment TMX-67 Receives Approvable Letter in the EU
March 10, 2008
- Nippon Shinyaku Enters the Field of OB-GYN with IKH-01
March 10, 2008
- Kyowa Hakko Receives Not-Approvable Letter from FDA for Istradefylline
March 10, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…